DOI QR코드

DOI QR Code

Outcomes for Pituitary Adenoma Patients Treated with Linac-Based Stereotactic Radiosurgery and Radiotherapy: a Long Term Experience in Thailand

  • Puataweepong, Putipun (Radiation and Oncology Unit, Department of Radiology, Ramathibodi Hospital, Mahidol University) ;
  • Dhanachai, Mantana (Radiation and Oncology Unit, Department of Radiology, Ramathibodi Hospital, Mahidol University) ;
  • Hansasuta, Ake (Department of Surgery, Ramathibodi Hospital, Mahidol University) ;
  • Dangprasert, Somjai (Radiation and Oncology Unit, Department of Radiology, Ramathibodi Hospital, Mahidol University) ;
  • Sitathanee, Chomporn (Radiation and Oncology Unit, Department of Radiology, Ramathibodi Hospital, Mahidol University) ;
  • Swangsilpa, Thiti (Radiation and Oncology Unit, Department of Radiology, Ramathibodi Hospital, Mahidol University) ;
  • Vitoonpanich, Patamintita (Radiation and Oncology Unit, Department of Radiology, Ramathibodi Hospital, Mahidol University) ;
  • Yongvithisatid, Pornpan (Radiosurgery Center, Faculty of Medicine, Ramathibodi Hospital, Mahidol University)
  • Published : 2015.08.03

Abstract

Background: The study analyzed the long term clinical outcomes of pituitary adenoma cases treated with the first Thailand installation of a dedicated Linac-based stereotactic radiation machine (X-Knife). Materials and Methods: A retrospective review of 115 consecutive pituitary adenoma patients treated with X-Knife at the Faculty of Medicine, Ramathibodi Hospital, Bangkok, Thailand from 1997 to 2003 was performed. Stereotactic radiosurgery (SRS) was selected for 21 patients (18%) including those with small tumors (${\leq}3cm$) located ${\geq}5mm$. from the optic apparatus, whereas the remaining 94 patients (82%) were treated with fractionated stereotactic radiotherapy (FSRT). Results: With a median follow-up time of 62 months (range, 21-179), the six-year progression free survival was 95% (93% for SRS and 95% for FSRT). The overall hormone normalization at 3 and 5 years was 20% and 30%, respectively, with average time required for normalization of approximately 16 months for SRS and 20 months for FSRT. The incidence of new hypopituitarism was 10% in the SRS group and 9% in the FSRT group. Four patients (5%) developed optic neuropathy (1 in the SRS group and 3 in the FSRT group). Conclusions: Linac-based SRS and FSRT achieved similar high local control rates with few complications in pituitary adenoma cases. However, further well designed, randomized comparative studies between SRS versus FSRT particularly focusing on hormone normalization rates are required.

Keywords

References

  1. Castinetti F, Brue T (2009). Radiotherapy and radiosurgery of pituitary adenomas. Presse Med, 38, 133-9. https://doi.org/10.1016/j.lpm.2008.09.012
  2. Grant RA, Whicker M, Lleva R, et al (2014). Efficacy and safety of higher dose stereotactic radiosurgery for functional pituitary adenomas: a preliminary report. World Neurosurg, 82, 195-201. https://doi.org/10.1016/j.wneu.2013.01.127
  3. Hasegawa T, Shintai K, Kato T, Iizuka H (2015). Stereotactic radiosurgery as the initial treatment for patients with nonfunctioning pituitary adenomas. World Neurosurg [Epub ahead of print].
  4. Kim JO, Ma R, Akagami R, et al (2013). Long-term outcomes of fractionated stereotactic radiation therapy for pituitary adenomas at the BC Cancer Agency. Int J Radiat Oncol Biol Phys, 87, 528-33. https://doi.org/10.1016/j.ijrobp.2013.06.2057
  5. Kong DS, Lee JI, Lim do H, et al (2007). The efficacy of fractionated radiotherapy and stereotactic radiosurgery for pituitary adenomas: long-term results of 125 consecutive patients treated in a single institution. Cancer, 110, 854-60. https://doi.org/10.1002/cncr.22860
  6. Kopp C, Theodorou M, Poullos N, et al (2012). Tumor shrinkage assessed by volumetric MRI in long-term follow-up after fractionated stereotactic radiotherapy of nonfunctioning pituitary adenoma. Int J Radiat Oncol Biol Phys, 82, 1262-7. https://doi.org/10.1016/j.ijrobp.2011.02.053
  7. Lee CC, Vance ML, Xu Z, et al (2014). Stereotactic radiosurgery for acromegaly. J Clin Endocrinol Metab, 99, 1273-81. https://doi.org/10.1210/jc.2013-3743
  8. Liao HI, Wang CC, Wei KC, et al (2014). Fractionated stereotactic radiosurgery using the Novalis system for the management of pituitary adenomas close to the optic apparatus. J Clin Neurosci, 21, 111-5. https://doi.org/10.1016/j.jocn.2013.03.024
  9. Liscak R, Jezkova J, Marek J (2013). Stereotactic radiosurgery of pituitary adenomas. Neurosurg Clin N Am, 24, 509-19. https://doi.org/10.1016/j.nec.2013.05.005
  10. Mayo C, Martel MK, Marks LB, et al (2010). Radiation dosevolume effects of optic nerves and chiasm. Int J Radiat Oncol Biol Phys, 76, 28-35. https://doi.org/10.1016/j.ijrobp.2009.07.1753
  11. Park KJ, Kano H, Parry PV, et al (2011). Long-term outcomes after gamma knife stereotactic radiosurgery for nonfunctional pituitary adenomas. Neurosurgery, 69, 1188-99. https://doi.org/10.1227/NEU.0b013e318222afed
  12. Puataweepong P, Dhanachai M, Dangprasert S, et al (2009). Comparison of conventional external radiotherapy and stereotactic radiotherapy in the treatment of pituitary adenoma. J Med Assoc Thai, 92, 382-9.
  13. Runge MJ, Maarouf M, Hunsche S, et al (2012). LINACradiosurgery for nonsecreting pituitary adenomas. Long-term results. Strahlenther Onkol, 188, 319-25. https://doi.org/10.1007/s00066-011-0052-5
  14. Sheehan JP, Starke RM, Mathieu D, et al (2013). Gamma Knife radiosurgery for the management of nonfunctioning pituitary adenomas: a multicenter study. J Neurosurg, 119, 446-56. https://doi.org/10.3171/2013.3.JNS12766
  15. Sheehan JP, Xu Z, Salvetti DJ, et al (2013). Results of gamma knife surgery for Cushing's disease. J Neurosurg, 119, 1486-92. https://doi.org/10.3171/2013.7.JNS13217
  16. Sun DQ, Cheng JJ, Frazier JL, et al (2010). Treatment of pituitary adenomas using radiosurgery and radiotherapy: a single center experience and review of literature. Neurosurg Rev, 34, 181-9.
  17. Tanaka S, Link MJ, Brown PD, et al (2010). Gamma knife radiosurgery for patients with prolactin-secreting pituitary adenomas. World Neurosurg, 74, 147-52. https://doi.org/10.1016/j.wneu.2010.05.007
  18. Weber DC, Momjian S, Pralong FP, et al (2011). Adjuvant or radical fractionated stereotactic radiotherapy for patients with pituitary functional and nonfunctional macroadenoma. Radiat Oncol, 6, 169. https://doi.org/10.1186/1748-717X-6-169
  19. Wilson PJ, De-Loyde KJ, Williams JR, Smee RI (2012). A single centre's experience of stereotactic radiosurgery and radiotherapy for non-functioning pituitary adenomas with the Linear Accelerator (Linac). J Clin Neurosci, 19, 370-4. https://doi.org/10.1016/j.jocn.2011.07.025

Cited by

  1. Histone deacetylase 11 suppresses p53 expression in pituitary tumor cells vol.41, pp.12, 2017, https://doi.org/10.1002/cbin.10834